These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24527796)

  • 1. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus.
    Fagone P; Muthumani K; Mangano K; Magro G; Meroni PL; Kim JJ; Sardesai NY; Weiner DB; Nicoletti F
    Immunology; 2014 Aug; 142(4):594-602. PubMed ID: 24527796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models.
    Stojanovic I; Cuzzocrea S; Mangano K; Mazzon E; Miljkovic D; Wang M; Donia M; Al Abed Y; Kim J; Nicoletti F; Stosic-Grujicic S; Claesson M
    Clin Immunol; 2007 Jun; 123(3):311-23. PubMed ID: 17449326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats.
    Mangano K; Sardesai NY; Quattrocchi C; Mazzon E; Cuzzocrea S; Bendtzen K; Meroni PL; Kim JJ; Nicoletti F
    Br J Pharmacol; 2008 Nov; 155(5):722-30. PubMed ID: 18776919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027.
    Mangano K; Sardesai N; D'Alcamo M; Libra M; Malaguarnera L; Donia M; Bendtzen K; Meroni P; Nicoletti F
    Eur J Pharmacol; 2008 May; 586(1-3):313-21. PubMed ID: 18374912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice.
    Stosic-Grujicic S; Cvetkovic I; Mangano K; Fresta M; Maksimovic-Ivanic D; Harhaji L; Popadic D; Momcilovic M; Miljkovic D; Kim J; Al-Abed Y; Nicoletti F
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1038-49. PubMed ID: 17148780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of VGX-1027 in PM
    Xu M; Li F; Wang M; Zhang H; Xu L; Adcock IM; Chung KF; Zhang Y
    Eur J Pharmacol; 2019 Jan; 842():373-383. PubMed ID: 30419239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.
    Zhang M; Yu G; Chan B; Pearson JT; Rathanaswami P; Delaney J; Ching Lim A; Babcook J; Hsu H; Gavin MA
    Arthritis Rheumatol; 2015 Oct; 67(10):2723-31. PubMed ID: 26097207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4
    Ahmad SF; Nadeem A; Ansari MA; Bakheet SA; Alasmari F; Alasmari AF; Al-Kharashi LA; Al-Qahtani QH; Attia SM
    Life Sci; 2019 Nov; 237():116930. PubMed ID: 31610190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonbilayer Phospholipid Arrangements Are Toll-Like Receptor-2/6 and TLR-4 Agonists and Trigger Inflammation in a Mouse Model Resembling Human Lupus.
    Wong-Baeza C; Tescucano A; Astudillo H; Reséndiz A; Landa C; España L; Serafín-López J; Estrada-García I; Estrada-Parra S; Flores-Romo L; Wong C; Baeza I
    J Immunol Res; 2015; 2015():369462. PubMed ID: 26568960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between CD8+ T cells in lupus-prone (NZB x NZW) F1 mice and healthy (BALB/c x NZW) F1 mice may influence autoimmunity in the lupus model.
    Karpouzas GA; La Cava A; Ebling FM; Singh RR; Hahn BH
    Eur J Immunol; 2004 Sep; 34(9):2489-99. PubMed ID: 15307181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor 8 deletion accelerates autoimmunity in a mouse model of lupus through a Toll-like receptor 7-dependent mechanism.
    Tran NL; Manzin-Lorenzi C; Santiago-Raber ML
    Immunology; 2015 May; 145(1):60-70. PubMed ID: 25424423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus.
    McMurray RW; Elbourne KB; Lagoo A; Lal S
    J Rheumatol; 1998 Dec; 25(12):2364-70. PubMed ID: 9858431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aconitine: A potential novel treatment for systemic lupus erythematosus.
    Li X; Gu L; Yang L; Zhang D; Shen J
    J Pharmacol Sci; 2017 Mar; 133(3):115-121. PubMed ID: 28302448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered toll-like receptor responsiveness underlies a dominant heritable defect in B cell tolerance in autoimmune New Zealand Black mice.
    Clark AG; Buckley ES; Foster MH
    Eur J Immunol; 2018 Mar; 48(3):492-497. PubMed ID: 29251774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4.
    Laird MD; Shields JS; Sukumari-Ramesh S; Kimbler DE; Fessler RD; Shakir B; Youssef P; Yanasak N; Vender JR; Dhandapani KM
    Glia; 2014 Jan; 62(1):26-38. PubMed ID: 24166800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression in B-1 cells from lupus-prone mice.
    Novaes E Brito RR; Xander P; Pérez EC; Maricato JT; Laurindo MF; De Lorenzo BH; Pellegrino R; Bernardo V; Lopes JD; Mariano M
    Immunol Invest; 2014; 43(7):675-92. PubMed ID: 24950194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White)F1 mice.
    Forestier C; Molano A; Im JS; Dutronc Y; Diamond B; Davidson A; Illarionov PA; Besra GS; Porcelli SA
    J Immunol; 2005 Jul; 175(2):763-70. PubMed ID: 16002672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gr-1(high) CD11b+ cells suppress B cell differentiation and lupus-like disease in lupus-prone male mice.
    Trigunaite A; Khan A; Der E; Song A; Varikuti S; Jørgensen TN
    Arthritis Rheum; 2013 Sep; 65(9):2392-402. PubMed ID: 23754362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous autoimmune disease in (NZB x NZW)F1 mice is ameliorated by treatment with methimazole.
    Mozes E; Zinger H; Kohn LD; Singer DS
    J Clin Immunol; 1998 Mar; 18(2):106-13. PubMed ID: 9533654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.